OzDx

How is it that the ceo have audacity to say hes pleased with the results after scamming so many shareholders? I just dont see how this recapitalisation was the only option leavin...

Understandable ...

Its really all about the perspective... Their oncology sales have been growing at a fast rate but now markets harsh on profitability. Not long ago it was all about growth at all cost. Once condit...

Thats just the EBITDA loss not the actual operating loss. It was just back of the hand calculation comparing last years Ebitda loss vs actual operating loss ...

Looks like theyre going to use all their cash they have now by the end of the year. whats the plan?...

I thought moodys resume was very underwhelming. Hopefully Im proven wrong ...

teleurstellend...

Yeah agreed... It has a track record of it being a money pit. Unless an institutional investor suddenly takes an interest in this money pit of a company, SP will continue to decline. ...

Means still noone wants to buy the stock ...

Well its better late than never. ...

December quarter update when? ...

Hopefully the bottom is in. Cash situation is still not very good but margin is improving and profitability is seemingly within its reach. Just need to prove in the next couple of quarters that they c...

Thought this was very positive...? Revenue down is expected in this economic climate but improving gross margin is a great news. ...

I guess its just lack of sellers at this price....

Still long way to go..id feel comfortable if bcart had more cash run way :(...

Good set of results on first glance. Continuing to increase oncology cartridge revenue led by US is surely a good sign. Hopefully gross margin continues to get better and more oncology centres to adop...

Hi FL, Sorry its the first time hearing about Parasortix so I cant make any comment on it but it does sound very promising for the whole space. I do think all of the things you menti...

Performance of Idylla KRAS assay on extracted DNA and de-stained cytology smears: Can we rescue small sample?AbstractObjective: KRAS is a frequently mutated gene in cancers, and with recent FDA-...

Im still here. Im actually still buying. Feeling adventurous ...

Nvm operating cash burn = EBITDA plus capital expenditure...

Can we expect BCART achieving profitability this FY? With product revenue guidance of EUR 50-55m and operating cash burn of eur 43-47m?...

Another positive result from study funded by memorial Sloan Kettering one of the leading oncology cancer centres in the world. pubmed.ncbi.nlm.nih.gov/35430374/...

Good result. Hopefully Bcart can turn this ship around! Growth rate has been steady strong, will see profitability soon while keeping the growth rate high. ...

Damn its crazy how much its dropping ...

Share price doesnt care about how much you bought them for. Id agree with @joe123 (obviously) Im a buyer today. Obviously Im not happy share price has been sliding but the growth is str...

Check out this article published in my home country :)pubmed.ncbi.nlm.nih.gov/35090771/Validation of EGFR mutation testing on cytological smears of lung cancer using the Idylla platform ...

Whoa i didnt know Cepheid has been a listed company for that long! I was just looking at the share price in the last 5 years it was listed :)Even though share price hasnt done well for Bio...

Cepheid actually didnt do that well in share price until Danaher announced theyd acquire it. Im afraid similar thing is happening with Biocartis :( ...

turn off the noise and watch the space. See; jcp.bmj.com/content/early/2022/01/17/...AbstractAims Somatic genetic testing in non-squamous, non-small cell lung ca...

Almost looks like a falling knife. Im going to take my chances and load up more here... Gltah...

Hold on... Is there a capital raise?? ...

Merry Christmas FL,The analysis time includes tumor sampling to histological analysis which takes 5.3 +- 3.6 working days and then its egfr request (decision making) to actual analysis on the...

Brand new article discussing use of Idylla as a screening test before NGSContribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGF...

This was going to be the case as idylla sars-cov-2 kit targets N and Orf1b. Surprised they took this long to announce it.. After all it was in silico analysis.... ...

I agree with you there. FDA approval on MSI Assay would be huge. Many clinical studies have been performed on their oncology assays at major hospitals in the US and most results suggest Idylla would b...

FL, Yes I am not that optimistic about the commercial success of Septicyte. Not because I think its a dud product but because I understand and see how long seemingly great products take to gain c...

I would really like to see Biocartis raise money by listing on the NASDAQ and build manufacturing line in the US but what do I know :)...

FL, Idylla SARS-CoV-2 test targets N and ORF1b genes which are known to be unaffected by Omicron variant. Imo, they wouldnt announce it unless they get their hands on Omicron variant positive sam...

Nothing surprising from this quarterly report as expected. Just good to see demand for oncology assays is strong and yoy growth remained strong. My investment thesis with Biocartis is that they mainta...

Many jobs advertised in the last few weeks. Ramping up staffing due to high demand? Also see they are advertising for a contract analyst based in the US. ...

Check out this new article discussing use of Idylla titled, Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay...

MB, understand that you can be looking at the exact same company and have different views in investing. Allocate accordingly if you cant stomach falling share price. Having a negative view on a c...

Looks like it was announced in 2020. Must be just about to actually start testing. ...

medicine.uq.edu.au/blog/2020/06/impro...This could be a game changer for immunexpress. Looking promising ...

FL, my understanding about the low sensitivity in that study you linked is because the sample population is patients with varying severity of Covid. They are all patients with covid. So what reference...

J Clin Pathol. 2021 Aug 16;jclinpath-2021-207726. doi: 10.1136/jclinpath-2021-207726Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is th...

*Fluff alert*I know this is just a fluff but one of Ark invests genomics analyst following head of Biocartis investor relations on Twitter. Should Biocartis list on the Nasdaq, I can see Ar...

You have to look beyond just the face value. Yes compared to H2/20 cartridge volume growth is single digit but biocartis main focus is in oncology. I would think covid testing was just a bonus. T...

Also remember, the cartridge sales mix is important. Well obviously see lower number growth in cartridge sales when compared to Q2, Q3 2020 but that would be due to declining sales in Sars-cov-2 ...

You have to understand the role of PocT devices in the diagnostic market and how it has penetrated the diagnostic market over many years... Yes low cost high throughput PCR platforms are the incumbent...